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Effect of corticosteroid therapy on 
influenza related mortality: a systematic 
review and meta-analysis 
 
Chamira Rodrigo1, Jo Leonardi-Bee2, Jonathan S Nguyen-Van-Tam2, Wei Shen Lim1 
ABSTRACT 
Background 
Most studies have reported that corticosteroid therapy adversely impacts influenza related outcomes. 
 
Methods 
Electronic databases were searched from inception to March 2013 for experimental and observational 
studies investigating systemic corticosteroid therapy for presumed influenza-associated 
complications. Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were 
adopted. Pooled odds ratios(ORs) and 95% confidence intervals(CIs) were estimated using random 
effects models, and heterogeneity was assessed using the I2 statistic. Quality of evidence was assessed 
using the GRADE (Grading Assessment, Development and Evaluation) system. 
 
Results 
We identified 16 eligible studies (n=3,039 individuals), all observational; 10 (n=1,497 individuals) were 
included in the meta-analysis of mortality, of which nine studied patients with influenza 
A(H1N1)pdm09. Risk of bias was greatest in the ‘comparability domain’ of the Newcastle-Ottowa 
scale, consistent with potential confounding by indication, and data specific to mortality were of low 
quality. Meta-analysis found increased odds of mortality (OR 2.12; 95%CI 1.36-3.29) associated with 
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corticosteroid therapy. Sub-group analysis of adjusted estimates from four studies with very low 
statistical heterogeneity found a similar association (OR 2.58; 95%CI 1.39-4.79).  
 
Conclusion 
No completed clinical trials were identified. Evidence from observational studies, with important 
limitations, suggest that corticosteroid therapy for presumed influenza-associated complications is 
associated with increased mortality.  
 
Keywords: Influenza; corticosteroid 
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INTRODUCTION 
Severe influenza is characterized by the induction of excessive proinflammatory cytokine 
production.1 ,2 Inflammatory cytokines may suppress the hypothalamic-pituitary-adrenal axis 
resulting in relative adrenal insufficiency, or compete with intracellular glucocorticoid receptor 
function resulting in peripheral tissue steroid resistance.3 Corticosteroids downregulate 
proinflammatory cytokine transcription and have been shown to improve innate immunity in 
patients with septic shock.4 ,5. 
 
Based on theoretical considerations and evidence of benefit in severe sepsis, corticosteroids have 
been used inconsistently in the management of severe influenza and influenza-related Acute 
Respiratory Distress Syndrome (ARDS). 6-8  During the 2009 influenza pandemic, 37 – 55% of patients 
admitted to intensive care units (ICUs) in Europe received corticosteroids as part of their treatment. 
9-11 Subsequent analysis of these cohorts found corticosteroids to be associated with no, or increased 
risk of mortality. 9-11 One randomised, controlled trial of corticosteroids in ICU admitted patients 
with influenza A(H1N1)pdm09  failed to recruit sufficient patients before the end of the pandemic.12  
A randomised, controlled trial of dexamethasone in  avian influenza A(H5N1) infection also failed to 
recruit sufficient patients.13  Considerable uncertainty remains regarding the impact of 
corticosteroids in the treatment of influenza. 
 
We aimed to systematically review all experimental and observational studies assessing the effect of 
corticosteroids in the treatment of presumed influenza-associated complications on clinical 
outcomes, regardless of influenza virus subtype or clinical setting. The primary outcome measures 
were mortality and admission to intensive care.  
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METHODS 
This systematic review was conducted in accordance with Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines. The study protocol was registered with the Cochrane Database of Systematic 
Reviews (available at http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010406/abstract).  
 
Study eligibility criteria 
Randomised controlled trials (RCTs), quasi-experimental designs, and observational studies assessing 
the association of systemic corticosteroids in the treatment of presumed influenza-associated 
complications on clinical outcomes were included. The intervention could be an intravenous or oral 
preparation of corticosteroid given for any clinical reason coinciding with influenza infection; there 
was no restriction on the dose or duration of intervention. Studies with less than ten participants 
were excluded. We considered subjects of any age with clinically diagnosed influenza or influenza-
like illness, and/or microbiologically confirmed influenza.  
  
The primary outcome measures were 30-day mortality and rate of admission to intensive care units 
(ICUs); secondary outcome measures were hospital re-admission rate, length of stay, requirement 
for mechanical ventilation, and number and nature of adverse events attributable to corticosteroid 
use.  
 
Search strategy and study selection 
We searched MEDLINE (1946 to February week 3, 2013), EMBASE (1980 to March 2013), CINHAHL 
(1981 to March 2013), LILACS (1982 to Marc 2013), Web of Science (1985 to March 2013) and the 
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Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 2 (part of ‘The Cochrane Library’ 
www.thecochranelibrary.com-accessed 7 March 2013), which contains the Cochrane Acute 
Respiratory Infections Group's Specialised Register. Searches were conducted without language 
restrictions. The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy 
to identify randomised trials.14 The Scottish Intercollegiate Guidelines Network (SIGN) filter was used 
to identify observational studies. Core search terms relating to influenza (including influenzavirus A 
OR influenzavirus B OR influenza) AND the exposure of interest, that is corticosteroids (including 
corticosteroid OR adrenocorticosteroid OR corticoid OR hydrocortisone OR prednisolone) were used. 
In addition, abstracts presented at three major international infectious diseases conferences 
(Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); European Society of 
Clinical Microbiology and Infectious Diseases (ESCMID); and Asia Pacific Society of Infection Control 
(APSIC)) from 2010 to March 2013, the bibliographies of included studies, and the Controlled Trials 
Registry (www.controlled-trials.com) were screened. Four domain experts (see acknowledgements) 
were also individually contacted to identify relevant studies. Details of the literature search are 
shown in supplementary table 1.  
 
Screening, data extraction and quality assessment  
Two authors (CR, WSL) independently reviewed all citations retrieved. Study selection was 
performed in two stages; screening of study titles and abstracts, followed by scrutiny of the full text. 
Non-English articles were translated to English before screening. Disagreements at any stage were 
resolved through discussion with a third investigator (JN-V-T). 
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Data from included studies were independently extracted by two investigators using a previously 
piloted proforma (CR extracted data from all included studies; JLB, JN-V-T and WSL each extracted 
data from one third of studies).  
 
Two investigators (CR, JLB) independently assessed the methodological quality of included studies at 
the outcome level using the Cochrane ’Risk of bias’ tool and the Newcastle-Ottawa Scale (NOS). 14 
Differences in methodological quality assessment were resolved by referral to a third investigator 
(JN-V-T). The overall quality of evidence for the main outcome of interest was assessed using the 
Grading Assessment, Development and Evaluation (GRADE) system.15 Summary of findings tables 
were constructed using GRADE profiler software, version 3.6.  
 
Data analysis 
Dichotomous outcome data from individual studies were extracted as tabulated data from which risk 
ratios (RR) or odds ratios (OR) and 95% confidence intervals (CI) were estimated. Adjusted outcome 
measures were extracted as ORs or hazard ratios (HR) with 95% CIs, and presented separately in 
pooled analyses. For normally distributed continuous data, mean difference or standardised mean 
difference with corresponding 95% CIs were calculated. Medians and inter-quartile ranges were 
reported for continuous data that were not normally distributed.  
 
Meta-analysis was performed using random effects models.  Heterogeneity was assessed using the I2 
statistic; when substantial (I2 > 75%), data were not pooled for meta-analysis. Publication bias was 
assessed using funnel plots. Of the studies included in the meta-analysis of mortality, sub-group 
analysis was performed according to influenza subtype. All statistical analyses were performed in 
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Review Manager, version 5.2 (The Nordic Cochrane Centre and the Cochrane Collaboration, 
Copenhagen, Denmark). 
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RESULTS 
Study selection  
The search identified 2,668 articles. After removal of duplicates (n=604), 2,064 articles remained. Of 
these, 1996 were excluded after screening of titles and abstracts and 52 were excluded after 
scrutiny of the full text (figure 1). The main reason for the exclusion of 52 articles was lack of 
relevant outcome data according to corticosteroid use.  Of 16 articles included in the systematic 
review, 10 were included in the meta-analysis of mortality 9-11 ,16-22 while six were included in the 
narrative synthesis only; three investigated corticosteroid therapy prior to the diagnosis of 
influenza,23-25  and three reported outcomes other than mortality according to corticosteroid use. 26-
28  
 
Study characteristics 
The study designs and participant characteristics of included studies are summarised in table 1.9-11 ,16-
28 All were observational designs.  Outcome data according to corticosteroid use were reported for 
3,039 individuals. All studies were conducted, at least in part, within a hospital setting: six studies 
consisted only of individuals admitted to ICUs (n=1,063); eight studies investigated admissions to 
both ICUs and hospital wards (n=1,627); one included individuals from non-ICU wards only (n=143); 
and one investigated both out-patients and in-patients (n=206).  There were 13 studies of influenza 
A(H1N1)pdm09 (n=2,652), two of interpandemic (seasonal) influenza (n=349) and one of avian 
influenza A(H5N1) (n=38). 
 
The median age of the cohort or corticosteroid treatment groups varied from 8-51 years(11 studies). 
Disease severity of patients at baseline was recorded according to corticosteroid therapy in seven 
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studies (n=1,292); 9-11 ,16 ,19 ,21 ,26 in three, (n=543)  baseline disease severity was higher in the 
corticosteroid treated group (table 1).11 ,16 ,21   
 
Seven studies reported the doses or regimens of corticosteroid administered; the mean/median 
dose of corticosteroid therapy was 67.5-117.5 mg of prednisolone equivalent per day in four 
studies,10 ,11 ,16 ,22 and regimens of methylprednisolone 1-6mg per kg per day were used in three 
studies.18 ,19 ,28 The median duration of corticosteroid therapy varied from 5.1-11.0 days (4 studies). 
 
Risk of bias of included studies 
The risk of bias for 24 reported outcomes are summarised in supplementary table 2. A maximum of 
4 stars for the ‘selection’ domain, 2 stars for the ‘comparability’ domain and 3 stars for the 
‘outcome’ domain (NOS) was achieved in 13/24, 6/24 and 21/24 reported outcomes in the included 
studies, respectively. Risk of bias specific to outcomes was greatest in the ‘comparability domain’ 
due to inadequate adjustment for differences in baseline characteristics and disease severity. 
 
 
Data synthesis and quantitative analysis 
The thirteen studies of influenza A(H1N1) reported no difference or greater mortality associated 
with corticosteroid use. The single study of influenza A/H5N1 found that corticosteroid therapy was 
associated with increased mortality following adjustment for neutropenia as a marker of disease 
severity.18 Two studies of seasonal influenza failed to find any benefits associated with corticosteroid 
therapy.23 ,25 The inclusion criteria in these studies included any influenza-related hospital admission 
or ICU admission, severe respiratory failure ((ARDS) or requiring mechanical ventilation), septic 
shock, multi-organ failure or ‘critical illness’. However, it was not clear why some patients within 
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these cohorts received systemic corticosteroid therapy while others did not. In particular, whether 
corticosteroid therapy was initiated primarily for treatment of unstable co-morbid illnesses 
(including asthma and chronic obstructive pulmonary disease (COPD)) was not apparent.  
 
Mortality 
Due to heterogeneity in the reporting of timing of mortality from hospital admission, stratification 
by 30-day mortality was not possible, therefore mortality was considered as reported by individual 
studies (table 2). Meta-analysis of 10 studies (n=1,497 patients) revealed a significantly higher odds 
of mortality with corticosteroid use (OR 2.12; 95% confidence interval (CI) 1.36-3.29), with moderate 
statistical heterogeneity (I2=40%) (figure 2). Sub-group analysis of four studies reporting adjusted 
odds ratios showed a similar association (OR 2.82; 95%CI 1.61-4.92) with very low heterogeneity 
(I2=0%). Unadjusted mortality was not associated with corticosteroid use (OR 1.74; 95%CI 0.91-3.34; 
six studies); however, in a post-hoc sensitivity analysis of unadjusted mortality estimates excluding 
the single study which showed a trend towards benefit,20  corticosteroid use was associated with 
greater odds of mortality (OR 2.02; 95%CI 1.19-3.43), with moderate statistical heterogeneity 
(I2=39%). There was no clear indication of publication bias on funnel plot analysis of the ten studies 
included in the meta-analysis. The quality of evidence specific to mortality was assessed as low by 
GRADE criteria (supplementary table 3). 
 
Two studies included in the meta-analysis also reported adjusted HRs for mortality associated with 
corticosteroid therapy; the first reported harm (HR 2.59; 95%CI 1.42 – 4.73) following adjustment for 
immunosuppression, disease severity (SAPS3) and vasopressor use,10 while the second found no 
significant association with mortality (HR 1.06; 95%CI 0.63-1.80) following adjustment for disease 
severity (APACHEII) and co-morbid illnesses.9 These studies were not pooled due to high statistical 
heterogeneity (I2=79%). 
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ICU admission, mechanical ventilation, length of stay and nosocomial infections 
Studies reporting these outcomes are summarised in tables 3 and 4. Only one study reported 
adjusted estimates of effect; critical disease (defined as ≥1 of death, respiratory failure, septic shock, 
failure or insufficiency of ≥2 non-pulmonary organs, mechanical ventilation, or ICU admission) was 
associated with early corticosteroid use (≤72 hours) in comparison to late or no corticosteroid 
therapy following adjustment for co-morbid illnesses, age, pregnancy and obesity (adjusted RR 1.8, 
95%CI 1.2-2.8).  Meta-analysis of individual outcomes could not be performed due to high statistical 
heterogeneity across studies. 
 
Sub-group analyses 
Pooled sub-group analysis of 9 studies of influenza A(H1N1)pdm09 only found corticosteroid  use to 
be associated with greater odds of mortality (OR 2.00, 95%CI 1.26-3.16) with moderate statistical 
heterogeneity (I2= 42%).  
 
Studies reporting outcomes according to different corticosteroid regimens are summarised in table 
5. Outcomes stratified according to age groups (children versus adults) and route of corticosteroid 
administration (intravenous versus oral) were not reported in the studies included in this review. 
 
Systemic corticosteroids prior to the diagnosis of influenza  
A study of corticosteroids for the treatment of graft versus host disease in haematopoietic stem cell 
transplant (HSCT) recipients in the two weeks prior to the diagnosis of seasonal influenza found no 
observed differences in time to death between individuals receiving low dose corticosteroid  therapy 
(<1mg/kg/day of methylprednisolone) (adjusted HR 1.1, 95%CI 0.4-3.6) or high dose corticosteroid  
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therapy (≥1mg/kg/day of methylprednisolone) (adjusted HR 1.1, 95%CI 0.3-3.5), in comparison to no 
prior corticosteroid  therapy.23 A mixed cohort of out-patients and in-patients with seasonal 
influenza reported increased odds of ‘complicated influenza’ (defined as the need for hospitalisation 
due to pneumonia, neurological complications, invasive bacterial infection, myocarditis or 
pericarditis) associated with corticosteroid therapy (adjusted OR 12.19, 95%CI 3.26-45.53; 
p=0.0002).25 
 
In one study of individuals hospitalised with influenza A(H1N1)pdm09, corticosteroid therapy in the 
90-days prior to hospital admission was independently associated with poor outcome (defined as a 
composite outcome of ICU admission and death) (adjusted OR 3.37, 95%CI 1.39–8.20).24  
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DISCUSSION 
To our knowledge, this is the first systematic review and meta-analysis to investigate the impact of 
corticosteroids on clinically relevant outcomes in individuals with presumed influenza-associated 
complications, unrestricted by influenza sub-types. The main findings are: 1) there are no completed 
RCTs, only observational studies; 2) available data suggests corticosteroid therapy is associated with 
greater odds of mortality. 
 
These findings must be viewed in the light of two important considerations.  Firstly, the indications 
for corticosteroid therapy were not fully specified in many studies.  In some instances, the stated 
rationale was ARDS and septic shock.9 ,10 ,16 ,22 However, at one extreme, corticosteroid therapy may 
have been used as ‘a last attempt’ in individuals with refractory illness. Conversely, they may have 
been used to treat less severe underlying comorbid illnesses such as exacerbations of asthma. The 
majority of studies included in this review relate to the 2009 pandemic when revised guidance from 
the World Health Organization(WHO) in February 2010 would have applied.29  However, adherence 
to that guidance which recommended that ‘patients who have severe or progressive clinical illness, 
including viral pneumonitis, respiratory failure, and ARDS due to influenza virus infection, should not 
be given systemic corticosteroids unless indicated for other reasons or as part of an approved 
research protocol’30 is not known. Over the same period, the ‘Surviving Sepsis Campaign’ 
recommended the use of corticosteroid therapy only in the setting of vasopressor dependent septic 
shock.31 The use of corticosteroids in the context of influenza infection but for different clinical 
indications (notable asthma) has been previously shown to be associated with different outcomes;32 
this may reflect both the different mechanisms of action of corticosteroids depending on the 
underlying pathophysiology and the impact of bias by indication in reports from observational 
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studies. This is compounded by the lack of consistent adjustment for disease severity across 
available studies. 
 
The second consideration relates to the doses of corticosteroids used. These were poorly specified in 
many instances and where reported, a higher daily dose was used than is typically recommended 
(prednisolone equivalent ≤ 50 mg daily) for the treatment of septic shock or exacerbations of 
airways disease such as asthma. 31 ,33 Variability in corticosteroid dose and administration schedule 
are both factors associated with treatment outcomes in the setting of severe sepsis; in particular, 
high-doses given in short bursts have not been associated with benefit compared to low doses given 
for longer durations (≥ 5 days).34 The use of higher doses of corticosteroids may explain the greater 
risk from secondary bacterial pneumonias due to S. aureus, K. pneumoniae, A. baumannii and P. 
aeruginosa observed with corticosteroid therapy in some studies.16  
 
The mechanisms behind potential harm from corticosteroids, aside from the risks from nosocomial 
infections, are not well defined. In patients with influenza A(H3N2) infection, systemic corticosteroid 
use for exacerbations of asthma or COPD was found to be associated with delayed viral clearance.35 
In turn, slower clearance of viral load was associated with mortality from ARDS in patients with 
influenza A (H1N1)pdm09 virus infection.36 Though causation cannot be inferred from these studies, 
exposure to systemic corticosteroids without concurrent antiviral treatment, as was likely for some 
patients in the studies reviewed, may proffer the highest risk of harm. 25 ,27  
 
Review findings in context 
A large (n=220), multicentre, prospective cohort study of individuals admitted to ICUs across Europe 
with influenza A/H1N1 was not included in this review due to overlapping study populations; it 
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found no association between corticosteroid use on ICU admission and ICU mortality, following 
adjustment for age, co-morbid illnesses and disease severity (adjusted HR 1.3, 95% CI 0.7–2.4, p = 
0.4).7 The estimates of mortality in this review are also in contrast to the evidence base from clinical 
trials of corticosteroids in the setting of other severe infections. Specifically, in a meta-analysis of 17 
RCTs (n=2,138) of corticosteroids in severe sepsis, sub-group analysis found prolonged low-dose 
corticosteroid therapy was associated with lower 28-day mortality;34  and in a meta-analysis of 9 
RCTs (n=1,001) of adults with community-acquired pneumonia (CAP), sub-group analysis of severe 
CAP revealed a survival benefit associated with corticosteroids.37  Larger trials of corticosteroid 
therapy in severe CAP are currently in progress and should provide more robust data within the next 
few years.38-40 In the setting of ICU-acquired pneumonia, a prospective cohort study of 316 patients 
found higher 28-day mortality with corticosteroid treatment in a propensity score adjusted 
analysis.41 
 
Strengths and weaknesses 
For this systematic review, no restrictions were placed on the demographics of included participants, 
study settings nor influenza subtypes. However, the available evidence identified consisted solely of 
observational data.  A high degree of correlation between corticosteroid therapy and potential 
confounders for measured outcomes (such as disease severity and the presence of co-morbid illness) 
was noted in some studies; hence unadjusted effect estimates are likely to be confounded by 
indication.11 ,16 ,21 ,22 Other important variables associated with influenza-related mortality including 
time to hospitalization, use and time to initiation of antiviral therapy and the presence of respiratory 
failure at commencement of corticosteroid therapy were inconsistently reported in the included 
studies.  The pooled analysis of mortality showed moderate statistical heterogeneity which may 
have been due to the inclusion of unadjusted estimates of mortality,  and a single outlying study 
demonstrating a trend towards benefit related to corticosteroid therapy.20 Clinical heterogeneity 
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was apparent across included studies. Specifically, disease severity was measured using a wide 
variety of clinical risk scores and mortality was reported at different time points; the rationale for 
corticosteroid use was inconsistent across studies; there was variation in the treatment groups with 
regard to the timing, dosage, duration and type of corticosteroid used; and the co-interventions for 
the control groups across studies were not uniform as varying proportions of adults were treated 
with antivirals and/or antibiotics.  
 
Implications of findings 
This systematic review highlights the fact that a firm conclusion regarding the value of corticosteroid 
therapy for influenza cannot be drawn from the current evidence base alone. The lack of sufficient 
data on the indications for corticosteroid therapy and the differing dosing schedules adopted were 
major limitations given the importance of these factors on the therapeutic potential of 
corticosteroids. There is a clear need for more robust evidence through the conduct of well-designed 
randomised, controlled trials on the role of corticosteroids, particularly at low doses; relevant groups 
of patients that should be tested include severely ill patients with complications of influenza 
including primary viral pneumonia, ARDS and septic shock. Less pressing is the need for trials in non-
severely ill patients with influenza-related exacerbations of underlying obstructive airways disease 
such as asthma and COPD. In the meantime, the findings from this review support the existing 
recommendations from the WHO that corticosteroids should not be used in the treatment of 
influenza infection, unless indicated for other reasons such as vasopressor dependent septic shock; 
or as part of an approved research protocol. 
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TABLES AND FIGURES 
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Studies included in meta-analysis 
 
 
Study/year 
(country) 
Design Setting/ 
Inclusion 
criteria 
CS given (n) CS not 
given 
(n) 
Demographics Disease severity 
scores 
Corticosteroid therapy 
dose/timing/ 
duration 
Outcomes reported 
 
Influenza A(H1N1)pdm09 
 
Brun-
Buisson 
2011 
(France)10 
Multicentre 
retrospective 
analysis of 
prospectively 
collected data 
ICU/ severe 
respiratory 
failure (ARDS 
or MV) 
83 (early CS 
50 and late 
CS 33) 
125 Median age (years): no 
CS 45 (35–55); CS 49 
(34–56) 
Immunosuppression: 
no CS 18.4%; CS 21.7% 
Median SAPSIII  
cohort 52.0(44.0-
64.0); no CS 53.0 
(46.0-66.0); CS 
group 51.0 (44.0-
61.0) ;p=0.25  
Median daily dose: 270 
(200-400) mg of 
hydrocortisone equivalent 
Timing: within median 1 
day (0-6) of MV  
Duration: median 11 days 
(I6-20) 
Hospital mortality, 
Length of ICU stay, 
Adverse events 
Diaz 2012   
(Spain)9 
Multicentre 
retrospective 
analysis of 
prospectively 
collected data 
ICU/ILI; 
respiratory 
failure 
requiring ICU 
admission;  
136  236 Mean age (years): no 
CS 43.6(±13.6); CS 
43.1(12.9) 
Asthma: no CS 18%; CS 
21% 
COPD: no CS 27%; CS 
18% 
Mean (SD) 
APACHEII:  
no CS group 
12.5(±6.7); CS 
group 13.2(±6.3) 
(p=0.318) 
Not reported ICU mortality, MV, 
LOS 
Kim 2011  
(South 
Korea)16 
Multicentre 
retrospective 
cohort/case 
control 
ICU/age ≥ 15 
years; presence 
of critical 
illness 
107  138 Mean age (years): no 
CS 54.1(±19.3); CS 
56.9(±17.2) 
Asthma: CS 9%; no CS 
7% 
COPD: CS 13%; no CS 
4% 
 
Mean (SD) 
APACHE II: no CS 
group 17.5(±8.5); 
CS group 
21.2(±7.7); 
p=0.001 
Dose: median pred 
equivalent 75 (50-81) 
mg/day 
Duration: median days 6 
(3-14) 
 
Mortality (14-day, 
30-day and 90-day), 
LOS, acquired 
infections 
Li 2012 
(China-
Anhui 
province)17 
Multicentre 
retrospective 
cohort 
In-hospital/ 
pregnant, 
severe disease 
27 19 Median age (years): 
adults who died 21(18-
31) and survivors 
21(18-27) 
 
Not reported Not reported Mortality  
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Linko 2011   
(Finland)11 
Multicentre 
prospective 
cohort 
ICU/admissions 
with influenza 
72 60 Median age (years): no 
CS 44(25-57); CS 51(40-
56) 
COPD: no CS 5%; CS 8% 
Other obstructive 
pulmonary disease: no 
CS 23%; CS 21% 
Median SAPSII: 
no CS 22(15-30), 
CS 31(24-36); 
p=0.001 
Methylpred and/or 
hydrocortisone 
Dose: Mean (SD) of highest 
methylpred dose 94(±43) 
mg and hydrocortisone 
214(±66) mg 
Timing: Median(IQR) days 
after symptom onset 
5.0(2.8-8.3) 
In-hospital 
mortality, MV, LOS 
Mady 2012   
(Saudi 
Arabia)19 
Single centre 
retrospective 
cohort 
ICU/influenza 
with 
respiratory 
failure 
43  43 Cohort mean age 
(years): 40.8 
Asthma or COPD: 
38.3% 
Mean APACHEIV: 
110.5 versus 
100.6 (p>0.05) 
not specified for 
which treatment 
group 
Methylpred 
Dose: 1mg/kg per day for 7 
days 
Mortality 
Sertogullari
ndan  
2011 
(Turkey)20 
Single centre 
prospective 
cohort 
ICU/severe 
community-
acquired 
pneumonia and 
influenza 
11 9 Cohort median age 
(years): 36 (15-72) 
COPD: 10% 
 
Not reported Not reported Mortality 
Viasus 2011 
(Spain)21 
Multicentre 
prospective 
cohort study 
In-hospital/ 
non-
immunosuppre
ssed, admitted 
> 24 hours 
37 
 
129 Median age (years): no 
CS 35 (28-47); CS 44 
(36-53) 
Chronic pulmonary 
disease: no CS 17.1%; 
CS 45.9% 
Number in high 
risk PSI classes: 
CS 8 (21.6); 
 no CS 8 (6.4); 
p<0.05 
Duration: Median days 9(5-
13.5) 
 
Severe disease  
(composite 
outcome of ICU 
admission/ death), 
acquired infection 
Xi 2010 
(China-
Beijing)22 
Multicentre 
retrospective 
cohort study 
In-hospital/ age 
≥18 years 
52 103 Cohort mean age 
(years):  43 (±18.6) 
COPD: 6.5% 
Not reported Dose: daily median dose 
equivalent to methylpred 
80mg (IQR 80-160mg)  
In-hospital 
mortality 
 Sub-group analysis 
of mortality by CS 
dose 
23 
 
 
Avian influenza A(H5N1) 
  
 
Liem 2009 
(Vietnam)18 
Multicentre 
retrospective 
cohort 
In-hospital/ 
hospitalised 
patients with 
influenza 
29 38 Cohort median age 
(years): 25 (16-42) 
 
Not reported Dose: methylpred 1-
3mg/kg/day for 7 days 
In-hospital 
mortality 
 
Studies not included in meta-analysis 
 
Influenza A(H1N1)pdm09 
 
 
Delgado-
Rodriguez 
2012  
(Spain)24 
Multicentre 
prospective 
cohort 
In-hospital/ILI, 
RTI, septic 
shock, multi-
organ failure 
31 782 Cohort median age 
(years): 41 (19-55) 
 
Not reported Corticosteroid use 90-days 
prior to admission 
Poor outcome (ICU 
admission and in-
hospital death), 
LOS 
Han 2011   
(China-
Shenyang 
City)26  
Multicentre 
retrospective 
cohort 
In-hospital/ 
Age >3 years 
46 (early CS 
17 and late 
CS 29) 
37 Median age (years): no 
CS 38(5-75); CS 43(3-
70) 
 
 
Median PMEWS: 
no CS group 2(0-
5); CS group 2(0-
5) 
Methylpred and 
Dexamethasone 
Critical illness  
Jain 2009 
(USA)27  
Multicentre 
retrospective 
cohort 
In-hospital/ILI 
with hospital 
admission ≥24 
hours 
86 153 Cohort median age: 21 
years (21 days to 86 
years) 
Asthma: 28%; COPD: 
8%; 
Immunosuppression: 
15% 
Not reported 
 
 
Not reported Death/ICU 
admission versus 
survival/no ICU 
admission 
Kudo 2012 
(Japan)28  
Single centre 
retrospective 
cohort 
In-hospital/ 
Hospitalised 
patients with 
respiratory 
disorders 
46 12 Cohort median age 
(years): 8 (0-71) 
Asthma: 29.2% 
 
Not reported Dose: methylpred 1-1.5 
mg/kg, 2-4 times/day 
Duration: median 5.1 days 
Timing: median 2.1 days 
following symptom onset 
LOS 
24 
 
 
Interpandemic (seasonal) influenza 
 
 
Boudreault 
2011  
(USA)23 
Single centre 
retrospective 
cohort 
Non-ICU/HSCT 
recipients with 
RTI 
80 
(low dose 
43 and high 
dose 37) 
63 Median age (years): no 
CS 42 (32-51); low dose 
CS 42(28-53); high dose 
CS 40 (32-54) 
 
Not reported Highest dose in 2/52 
preceding influenza. Low 
dose (pred/methylpred <1 
mg/kg/day); high dose 
(pred/methylpred >=1 
mg/kg/day) 
MV, time to death, 
PVS 
Wu 2012 
(Taiwan)25 
Single centre 
prospective 
cohort 
Mixed cohort 
of out-patients 
and in-patients 
17 189 Age >=65 years in 
cohort: 12.6% 
Chronic lung disease: 
9.7% 
Malignancy: 8.7% 
Not reported Dose/duration: not 
reported 
Unclear if CS commenced 
prior to or following 
diagnosis 
Complicated 
influenza (requiring 
hospitalisation) 
 
CS, corticosteroid therapy; ICU, intensive care unit; HSCT, haematopoietic stem cell transplant; RTI, respiratory tract infection; ILI, influenza-like illness; 
COPD, chronic obstructive pulmonary disease; LDH, lactate dehydrogenase;  pred, prednisolone; methylpred, methylprednisolone; MV, mechanical 
ventilation; PVS, persistent viral shedding; LOS, length of stay; ARDS, adult respiratory distress syndrome; SAPS, Simplified Acute Physiology Score; APACHE, 
Acute Physiology and Chronic Health Evaluation; PMEWS, Pandemic Modified Early Warning Score; PSI, Pneumonia Severity Index; SOFA, Sequential Organ 
Failure Assessment; SD, standard deviation; IQR, inter-quartile range 
 
Numbers in brackets following medians and means are inter-quartile ranges and standard deviations, respectively 
 
Table 1: Summary of study cohorts in included studies 
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Study/year Outcome reported Mortality in CS 
treatment group 
n(%) 
Mortality in 
group not treated 
with CS n(%) 
Reported unadjusted 
risk of mortality  
Reported adjusted 
risk of mortality 
Variables included in 
model for adjusted 
estimates 
Brun-Buisson 2011 In-hospital mortality 28/83(33.8) 21/125(16.8) HR 2.39 (95% CI 1.32- 
4.31) 
aHR 2.59 (95% CI 
1.42 – 4.73) 
Immunosuppression, 
disease severity 
(SAPS3), vasopressor 
use 
Diaz 2012   ICU mortality 25/136(18.4) 41/236(17.4) HR 0.91 (95% CI 0.55-
1.48) 
aHR 1.06 (95% CI 
0.63-1.80) 
Disease severity 
(APACHEII), co-morbid 
illnesses 
Kim 2011  90-day mortality 
(also unadjusted 
estimates provided 
for 14-day and 30-
day) 
62/107(57.9) 37/138(26.8) OR 3.76 (95%CI 2.19-
6.44) 
aOR 2.20 (95%CI 
1.03-4.71) 
age, disease severity 
(SOFA), MV, 
lymphocyte count, 
propensity score) 
Li 2012 Mortality 6/27(22.2) 1/19(5.2) OR 5.14 (95%CI 0.56- 
46.82) 
Not reported N/A 
Liem 2009 In-hospital mortality 17/29(58.6) 9/36(25.0) OR 4.25 (95%CI 1.48-
12.22) 
aOR 4.11 (95%CI 
1.14-14.83) 
Neutropenia as 
surrogate for severity 
Linko 2011 In-hospital mortality 8/72(11.1) 2/60(3.3) OR 3.63 (95%CI 0.74- 
17.77) 
aOR 3.3 (95% CI 0.5 
to 23.4) 
Disease severity 
(SAPS2) 
Mady 2012 In-hospital mortality 20/43(46.5) 10/43(23.2) OR of 2.87 (95%CI 
1.14—7.25) 
Not reported N/A 
Sertogullarindan  
2011 
Mortality 3/11(27.3) 6/9(66.7) OR 0.19 (95%CI 0.03- 
1.28) 
Not reported N/A 
Viasus 2011 Mortality (primary 
outcome was ‘severe 
disease’=ICU 
admission/death) 
3/37(8.1) 4/129(3.1) OR 2.76 (95%CI 0.59-
12.92) 
Not reported N/A 
Xi 2010 In-hospital mortality 17/52(32.7) 10/103(9.7) OR 4.52 (95%CI 1.89-
10.81) 
aOR 3.67 (95% CI 
0.99-13.64) 
Ethnicity, co-morbid 
illness, symptoms at 
onset, laboratory tests 
 
26 
 
CS, corticosteroid; HR; hazard ratio; aHR, adjusted HR; OR, odds ratio; aOR, adjusted OR; RR, risk ratio; ICU, intensive care unit; MV, mechanical; SAPS, 
Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation ventilation 
 
Table 2: Summary of mortality according to corticosteroid use in studies included in meta-analysis  
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Outcome Study/year Group treated with 
corticosteroids 
n(%) 
Group not treated 
with 
corticosteroids 
n(%) 
Unadjusted estimate of effect 
Critical disease Han 2011 Early CS 
12/17 (70.6) 
Late or no CS 
26/66 (39.4) 
RR 1.8, 95% CI 1.2–2.8† 
Composite outcome 
of ICU admission/ 
death 
Jain 2009 29/86 (33.7) 27/153 (17.6) OR 2.37, 95% CI 1.29-4.37 
Rate of MV Kim 2011 91/107 (85.0) 71/138 (51.4) OR 5.37, 95% CI 2.87-10.05 
Rate of MV Linko 2011 53/72 (73.6) 14/60 (23.3) OR 9.17, 95% CI 4.14-20.30 
Length of ICU stay 
median days (IQR) 
Brun-Buisson 
2011 
22 (13–39) 17 (11-30) p=0.11 
LOS  
mean days (SD) 
 
Kim 2011 30.8 (36.9) 
  
18.9 (20.0) p<0.001 
LOS 
median days (IQR) 
Kudo 2012 8.2 (5-14) 7.7 (3-14) p=0.607 
LOS 
Median days (IQR) 
Linko 2011 20 (12-34) 8 (5-13) p<0.001 
 
CS, corticosteroid; RR, risk ratio; aRR, adjusted risk ratio; OR, odds ratio; ICU, intensive care unit; MV, mechanical ventilation, LOS, length of stay 
† adjusted risk ratio 1.8, 95%CI 1.2-2.8 (following adjustment for co-morbid illnesses, age, pregnancy and obesity)  
Table 3: Summary of studies reporting clinical outcomes other than mortality 
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Adverse effect Study/year Group treated with 
corticosteroids n(%) 
Group not treated 
with corticosteroids 
n(%) 
Unadjusted estimate 
of effect 
ICU-acquired 
infection 
Brun-Buisson 2011 38/83 (45.8) 44/125 (35.2) OR 1.55, 95%CI 0.88-
2.74 
Hospital-acquired 
infection 
Kim 2011 54/107 (50.5) 24/138 (17.4) OR 4.84, 95%CI 2.71-
8.65 
Hospital-acquired 
infection 
Viasus 2011 6/37 (16.2) 4/129 (3.1) OR 6.05, 95%CI 1.61-
22.75 
 
ICU, intensive care unit; OR, odds ratio 
 
 
Table 4: Summary of studies reporting corticosteroid-related adverse events or nosocomial infection 
29 
 
Sub-group analysis Study Outcome Comments 
Early and late CS 
therapy compared with 
no CS therapy 
Brun-Buisson 2011 Hospital mortality 
Early CS: HR, 3.42, 95% CI 1.73–6.75; p=0.001 
Late CS: HR, 1.93, 95%CI, 0.84–4.43; P= 0.12 
Early treatment defined as ‘within 3 days of 
mechanical ventilation’ 
Propensity score adjusted analysis 
Early CS therapy versus 
late/no CS therapy 
groups combined 
Han 2011 Critical illness 
RR 1.8, 95%CI 1.2-2.8 
Early treatment defined as <72 hours from influenza-
like illness 
Multivariate analysis following adjustment for 
underlying co-morbid illnesses, age, pregnancy and 
obesity 
Low versus high dose CS 
therapy 
Xi 2010 In-hospital  mortality 
9/30 vs. 8/22, p = 0.854 
 
Low dose CS therapy defined as ≤ 80 mg 
methylprednisolone or equivalent daily dose 
Unadjusted outcome 
 
CS, corticosteroid; HR, hazard ratio; RR, risk ratio 
 
Table 5: Summary of studies reporting outcomes stratified according to different corticosteroid regimens 
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Figure 1: PRISMA flow diagram for article selection process 
 
Figure 2: Meta-analysis of studies reporting mortality 
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Supplementary table 1: Search strategy for MEDLINE (Ovid)- 1946 to present 
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MV, mechanical ventilation; LOS, length of stay; ICU, intensive care unit; 
† studies not included in meta-analysis (three studies investigating CS therapy before influenza 
diagnosis;23-25 three studies with no mortality data according to CS use26-28) 
 
Supplementary table 2: Risk of bias in observational studies using the Newcastle-Ottowa Scale 
33 
 
Supplementary table 3: GRADE assessment of mortality
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